Stocks News

LAST PRICE
42.2600
TODAY'S CHANGE (%)
Trending Down-0.9600 (-2.2212%)

Bid / Lots
42.0900/ 1
Ask / Lots
42.2600/ 10
Open / Previous Close
43.1000 / 43.2200
Day Range
Low 42.1800
High 43.1700
52 Week Range
Low 4.8250
High 50.7800
Volume
854,008
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024, from 13 hours ago by PR Newswire
  13 hours ago by PR Newswire
  Companies Mentioned: RNA
  Avidity to present poster on precision cardiology candidate at American Heart Association (AHA) Scientific Sessions 2024 taking place November 16-18, 2024
  Volume 11 of investor and analyst event series will be available via webcast November 12, 2024, at 8:00 a.m. ET
- Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024, from 13 hours ago by Dow Jones
  13 hours ago by Dow Jones
  Companies Mentioned: RNA
  
  Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024
- DJ Avidity Biosciences Price Target Maintained With a $60.00/Share by Needham, from 16 hours ago by Dow Jones
  16 hours ago by Dow Jones
  Companies Mentioned: RNA
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RNA/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 31, 2024 05:42 ET (09:42 GMT)
Yesterday
- DJ Avidity Biosciences Is Maintained at Buy by Chardan Capital, from 9:36AM ET on Wednesday Oct 30, 2024 by Dow Jones
  9:36AM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: RNA
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RNA/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 30, 2024 09:36 ET (13:36 GMT)
- Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy, from 8:00AM ET on Wednesday Oct 30, 2024 by PR Newswire
  8:00AM ET on Wednesday Oct 30, 2024 by PR Newswire
  Companies Mentioned: RNA
  Biomarker cohort for delpacibart braxlosiran (del-brax), the first potential therapy to target DUX4, is measuring changes in DUX4 regulated biomarkers; del-brax 2 mg/kg will be administered every six weeks

Today
- Sector Update: Health Care Stocks Softer Late Afternoon, from 6 hours ago by MT Newswires
  6 hours ago by MT Newswires
  Companies Mentioned: MRK, EQ, MDGL, MTNB
- Sector Update: Health Care, from 6 hours ago by MT Newswires
  6 hours ago by MT Newswires
  Companies Mentioned: MDGL
- Madrigal Pharmaceuticals' Shares Rise After Reporting Narrower Q3 Loss, from 12 hours ago by MT Newswires
  12 hours ago by MT Newswires
  Companies Mentioned: MDGL
- -- Earnings Flash (MDGL) MADRIGAL PHARMACEUTICALS Reports Q3 Loss $-4.92 Per Share, from 15 hours ago by MT Newswires
  15 hours ago by MT Newswires
  Companies Mentioned: MDGL
- Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates, from 15 hours ago by Dow Jones
  15 hours ago by Dow Jones
  Companies Mentioned: MDGL
- *DJ Madrigal Pharmaceuticals 3Q Loss/Shr $4.92 >MDGL, from 15 hours ago by Dow Jones
  15 hours ago by Dow Jones
  Companies Mentioned: MDGL
Yesterday
- Madrigal Pharmaceuticals to Present Multiple Rezdiffra(TM) (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting(R), from 8:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
  8:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: MDGL
Oct 28, 2024
- Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024, from 7:00AM ET on Monday Oct 28, 2024 by Dow Jones
  7:00AM ET on Monday Oct 28, 2024 by Dow Jones
  Companies Mentioned: KRYS
Oct 23, 2024
- DJ Madrigal Pharmaceuticals Is Maintained at Outperform by Oppenheimer, from 8:34AM ET on Wednesday Oct 23, 2024 by Dow Jones
  8:34AM ET on Wednesday Oct 23, 2024 by Dow Jones
  Companies Mentioned: MDGL
Oct 22, 2024
- DJ Madrigal Pharmaceuticals Price Target Maintained With a $390.00/Share by HC Wainwright & Co., from 7:30AM ET on Tuesday Oct 22, 2024 by Dow Jones
  7:30AM ET on Tuesday Oct 22, 2024 by Dow Jones
  Companies Mentioned: MDGL

Avidity Biosciences Inc
NASDAQ:RNAUnited States

Search Criteria

Today

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024, from 13 hours ago by PR Newswire

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024, from 13 hours ago by Dow Jones

DJ Avidity Biosciences Price Target Maintained With a $60.00/Share by Needham, from 16 hours ago by Dow Jones

Yesterday

DJ Avidity Biosciences Is Maintained at Buy by Chardan Capital, from 9:36AM ET on Wednesday Oct 30, 2024 by Dow Jones

Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy, from 8:00AM ET on Wednesday Oct 30, 2024 by PR Newswire

Peers Headlines

Today

Sector Update: Health Care Stocks Softer Late Afternoon, from 6 hours ago by MT Newswires

Sector Update: Health Care, from 6 hours ago by MT Newswires

Madrigal Pharmaceuticals' Shares Rise After Reporting Narrower Q3 Loss, from 12 hours ago by MT Newswires

-- Earnings Flash (MDGL) MADRIGAL PHARMACEUTICALS Reports Q3 Loss $-4.92 Per Share, from 15 hours ago by MT Newswires

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates, from 15 hours ago by Dow Jones

*DJ Madrigal Pharmaceuticals 3Q Loss/Shr $4.92 >MDGL, from 15 hours ago by Dow Jones

Yesterday

Madrigal Pharmaceuticals to Present Multiple Rezdiffra(TM) (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting(R), from 8:00AM ET on Wednesday Oct 30, 2024 by Dow Jones

Oct 28, 2024

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024, from 7:00AM ET on Monday Oct 28, 2024 by Dow Jones

Oct 23, 2024

DJ Madrigal Pharmaceuticals Is Maintained at Outperform by Oppenheimer, from 8:34AM ET on Wednesday Oct 23, 2024 by Dow Jones

Oct 22, 2024

DJ Madrigal Pharmaceuticals Price Target Maintained With a $390.00/Share by HC Wainwright & Co., from 7:30AM ET on Tuesday Oct 22, 2024 by Dow Jones